ResMed Shares Lag Healthcare Despite Strong Fiscal 2026 Results
RMD has trailed healthcare stocks over 12 months, but improving earnings, cash flow and buybacks complicate the bearish case.
Stocks
Markets, companies and the economy, from New York and Frankfurt to Istanbul and Tokyo.
Page 88 of 89
RMD has trailed healthcare stocks over 12 months, but improving earnings, cash flow and buybacks complicate the bearish case.
Stocks
Skyworks shares are surging on Qorvo deal progress, but the rally now carries execution, debt and valuation risks.
Stocks
Weak direct sales, China’s slump and a tariff-driven margin boost leave Nike investors waiting for evidence of durable recovery.
Stocks
Apple’s momentum is real, but Microsoft pairs faster cloud growth with a contracted enterprise pipeline that better supports its valuation.
Stocks
Amazon’s operating cash flow is surging, yet a $220 billion investment plan complicates the bullish case for AMZN shares.
Stocks
The new Ho Chi Minh City subsidiary creates a sales and distribution foothold, but Tesla has not disclosed launch timing or local production plans.
Stocks
Lowe’s offers thinner sales momentum but stronger payout coverage as weak housing demand keeps pressure on both retailers.
Stocks
AMD brings faster growth potential, but ASML’s monopoly on advanced lithography offers investors a sturdier way to play AI infrastructure.
Stocks
AST SpaceMobile has cash, contracts and satellites, but its valuation already assumes a near-flawless commercial rollout.
Stocks
GRMN has slipped from its August peak, but its three-month gain still outpaces technology stocks as earnings momentum strengthens.
Stocks
The Danish drugmaker is pairing a consumer-facing rebrand with a culture reset as Eli Lilly widens its lead in obesity medicines.
Stocks
Eaton’s power-infrastructure backlog contrasts with Rivian’s costly R2 ramp, making the choice hinge on certainty versus upside.
Stocks
The five-company list spans retail, healthcare, entertainment and mortgage assets, with yields ranging from about 4% to 14%.
Stocks
The recommendation strengthens Kirill Klip’s position as shareholders prepare to vote on a full board overhaul proposed by Eucalyptus Resources.
Stocks
Investors briefly questioned the spending engine behind the AI boom after Anthropic’s CEO urged companies to slow model development.
Stocks
A binding power contract with TVA would validate NuScale’s model, while another delay could expose the stock’s thin commercial foundation.
Stocks
The insurance broker will leave Nasdaq as new owners pair patient capital with an aggressive push into artificial intelligence.
Stocks
The GameStop and Uber chiefs made discretionary purchases, but the businesses they are betting on face very different investor tests.
Stocks
A weekend warning from AI leaders jolted semiconductor shares while investors rotated toward cybersecurity and less crowded trades.
Stocks
Novo Nordisk is shortening its public name as it prepares investors for a sharper strategic push in the obesity-drug race.
Stocks
Three midstream C-corps combine fee-based cash flow, rising dividends and simpler 1099 tax reporting for income investors.
Stocks
ISEMBYLD approval moves Scholar Rock into commercialization after a manufacturing setback delayed its first attempt last year.
Stocks
JPMorgan cut MARA to Underweight and lowered its target, reviving concerns about weak revenue and the payoff from its AI pivot.
Stocks
Applied Materials fell alongside major chip names after AI leaders urged a slower development pace, reviving questions about future infrastructure demand.
Stocks